Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly Limited
Oslo, Norway and Oxford, UK: 29th April 2021. No embargo.
Zelluna Immunotherapy AS announces an exclusive research collaboration with Etcembly Ltd to discover T cell receptors immune pattern recognition system EMLy™.
Zelluna Immunotherapy, the company pioneering allogeneic “off the shelf” TCR based natural killer (TCR-NK) cells for the treatment of cancer, and Etcembly, a start-up developing innovative machine learning techniques in immune pattern recognition for in silico discovery of novel TCR specificities, today announce an exclusive collaboration to discover TCRs with an initial focus on a widely expressed and well-validated solid cancer antigen.
TCR-NK products are a novel class of allogeneic cellular therapies that combine the inherent killing mechanism, efficiency, and the allogeneic nature of NK cells with the targeting capabilities of TCRs. TCR engineered NK cells may unlock the potential to treat a wide range of currently untreatable cancers.
“I am delighted that we have the opportunity to combine our proprietary TCR-NK platform with the high potential of Etcembly’s innovative approach to TCR discovery through the application of artificial intelligence. We are looking forward to working with the Etcembly team on breaking new ground in the discovery of highly potent TCRs for cancer immunotherapy. This collaboration forms part of our wider strategy for discovering TCRs which includes in-licensing and our own recently initiated discovery efforts.” said Luise Weigand, Head of Research at Zelluna
“We relish this unprecedented opportunity to work with Zelluna at such an early stage of our company – a testament to the confidence in our immune prediction platform EMLy™. This is the start of an exciting collaboration in pursuit of defining a new paradigm of learn drug discovery for immunotherapy.” said Michelle Teng, Founder CEO of Etcembly.
About Zelluna Immunotherapy AS
Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumour specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more information, please visit https://www.zelluna.com or firstname.lastname@example.org
About Etcembly Limited
Etcembly is a privately owned, Oxfordshire-based company. Its mission is to decode immune repertoires in health and disease by building a pioneering machine learning platform (EMLy™). EMLy™ will be the world’s leading health and disease immune database, to fulfil the vision of lean drug discovery for immunotherapy and personalised therapeutics across all patient groups globally.
Forward Looking Statement
While Zelluna and Etcembly believe any forward-looking statements in this press release are accurate, the statements represent Zelluna’s and Etcembly’s beliefs only as of the date of this press release. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Zelluna and Etcembly undertake) no intent or obligation to update the information contained in this press release as new information becomes available.